308 related articles for article (PubMed ID: 31754884)
41. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
Barrington DA; Dilley SE; Smith HJ; Straughn JM
Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
[TBL] [Abstract][Full Text] [Related]
42. Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.
Lesokhin AM; Bal S; Badros AZ
Cancer Immunol Res; 2019 Aug; 7(8):1224-1229. PubMed ID: 31371317
[TBL] [Abstract][Full Text] [Related]
43. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
[TBL] [Abstract][Full Text] [Related]
44. Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial.
Chen J; Quan M; Chen Z; Zeng T; Li Y; Zhou Y; Hai Y; Gao Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2651-2657. PubMed ID: 32623573
[TBL] [Abstract][Full Text] [Related]
45. Advanced and recurrent endometrial cancer: State of the art and future perspectives.
Tronconi F; Nero C; Giudice E; Salutari V; Musacchio L; Ricci C; Carbone MV; Ghizzoni V; Perri MT; Camarda F; Gentile M; Berardi R; Scambia G; Lorusso D
Crit Rev Oncol Hematol; 2022 Dec; 180():103851. PubMed ID: 36257537
[TBL] [Abstract][Full Text] [Related]
46. Immunotherapy of Colon Cancer.
Stein A; Folprecht G
Oncol Res Treat; 2018; 41(5):282-285. PubMed ID: 29705788
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers.
Ferriss JS; Williams-Brown MY
Curr Treat Options Oncol; 2019 Aug; 20(10):75. PubMed ID: 31444655
[TBL] [Abstract][Full Text] [Related]
48. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.
Lv JW; Li JY; Luo LN; Wang ZX; Chen YP
J Immunother Cancer; 2019 Jun; 7(1):159. PubMed ID: 31238988
[TBL] [Abstract][Full Text] [Related]
49. Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer.
Manogue C; Cotogno P; Ledet E; Lewis B; Wyatt AW; Sartor O
Oncologist; 2019 Apr; 24(4):444-448. PubMed ID: 30541755
[TBL] [Abstract][Full Text] [Related]
50. Predicting Tumor Response to PD-1 Blockade.
Ding L; Chen F
N Engl J Med; 2019 Aug; 381(5):477-479. PubMed ID: 31365807
[No Abstract] [Full Text] [Related]
51. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
Chen KH; Yuan CT; Tseng LH; Shun CT; Yeh KH
J Hematol Oncol; 2016 Mar; 9():29. PubMed ID: 27012666
[TBL] [Abstract][Full Text] [Related]
52. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.
Mandal R; Samstein RM; Lee KW; Havel JJ; Wang H; Krishna C; Sabio EY; Makarov V; Kuo F; Blecua P; Ramaswamy AT; Durham JN; Bartlett B; Ma X; Srivastava R; Middha S; Zehir A; Hechtman JF; Morris LG; Weinhold N; Riaz N; Le DT; Diaz LA; Chan TA
Science; 2019 May; 364(6439):485-491. PubMed ID: 31048490
[TBL] [Abstract][Full Text] [Related]
53. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers.
Ruiz-Bañobre J; Goel A
Gastroenterology; 2019 Mar; 156(4):890-903. PubMed ID: 30578781
[TBL] [Abstract][Full Text] [Related]
54. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
Song Y; Li Z; Xue W; Zhang M
Immunotherapy; 2019 Apr; 11(6):515-529. PubMed ID: 30860441
[TBL] [Abstract][Full Text] [Related]
55. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS
Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871
[No Abstract] [Full Text] [Related]
56. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
57. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
58. Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.
Yamashita H; Nakayama K; Ishikawa M; Ishibashi T; Nakamura K; Sawada K; Yoshimura Y; Tatsumi N; Kurose S; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31623180
[TBL] [Abstract][Full Text] [Related]
59. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
60. Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline
Dizon DS; Dias-Santagata D; Bregar A; Sullivan L; Filipi J; DiTavi E; Miller L; Ellisen L; Birrer M; DelCarmen M
Oncologist; 2018 Jun; 23(6):650-653. PubMed ID: 29472312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]